Related Experiment Video
Updated: Jan 14, 2026
06:32
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
6.5K
Bone metastases in germ cell tumor patients
Karin Oechsle1, Carsten Bokemeyer, Christian Kollmannsberger
1Department of Oncology/Hematology/Bone marrow transplantation/Pneumology, University Medical Center Eppendorf, Martinistr 52, 20246 Hamburg, Germany. k.oechsle@uke.de
Journal of Cancer Research and Clinical Oncology
|February 22, 2012
Summary
Bone metastases in germ cell cancer are linked to specific tumor types and locations. While high-dose chemotherapy shows promise, isolated bone relapses carry a poor prognosis, highlighting the need for targeted treatments.
Area of Science:
- Oncology
- Medical Research
Background:
- Limited data exists on bone metastases in germ cell cancer patients.
- Understanding characteristics, treatment, and outcomes is crucial.
Purpose of the Study:
- To analyze the characteristics, treatment, and outcomes of germ cell cancer patients with bone metastases.
- To evaluate the efficacy of high-dose chemotherapy (HD-CTX) in this patient group.
Main Methods:
- Retrospective analysis of 434 poor-prognosis germ cell cancer patients from two phase II trials.
- Patients received primary high-dose chemotherapy (HD-CTX).
Main Results:
- 9% of patients had primary bone metastases, more common in mediastinal tumors, yolk sac histology, and with liver metastases.
- HD-CTX achieved an 85% overall response rate; 63% had progression-free survival.
- Skeletal relapses were rare (0.9%) but associated with a dismal outcome, with all patients dying within 1 year.
Conclusions:
- Bone metastases in germ cell cancer are associated with primary mediastinal nonseminoma, yolk sac histology, and liver metastases.
- HD-CTX as first-line treatment resulted in 63% long-term progression-free survival.
- Rare skeletal relapses indicate a poor prognosis, underscoring the need for improved management strategies.
